Combretastatin A-4 Phosphate

DRUG2 trials

Sponsors

Mateon Therapeutics, Johns Hopkins University

Conditions

AMDAge-related Macular DegenerationCNVChoroidal NeovascularizationCombretastatin A4 PhosphateMyopia, Degenerative

Phase 1

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT01570790

Johns Hopkins UniversityAge-related Macular Degeneration, AMD, Choroidal Neovascularization +2

Start: 2003-05-31End: 2005-06-30Updated: 2017-12-06

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT01570790

Johns Hopkins UniversityAge-related Macular Degeneration, AMD, Choroidal Neovascularization +2

Start: 2003-05-31End: 2005-06-30Updated: 2017-12-06

Phase 2

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedNCT01423149

Mateon TherapeuticsChoroidal Neovascularization, Myopia, Degenerative

Start: 2005-03-31End: 2007-01-31Updated: 2011-11-01